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he Dutch philosopher, Desiderius Erasmus, is 
attributed as first coining the phrase ‘prevention is 
better than cure’. Nowhere has this maxim been 
more applicable than in the field of dementia 
care, where curative treatment options remain 
frustratingly elusive. This is particularly worrying given the 
stark epidemiological evidence for the condition. Globally, 
about 50 million people have dementia, with nearly 10 million 
new cases every year (World Health Organization, 2019). In 
relation to the UK, there are an estimated 850 000 people with 
dementia, with numbers set to rise to over 1 million by 2025 
(Alzheimer’s Society, 2019a). Notably, deaths due to dementia 
and Alzheimer’s disease increased for the third consecutive 
year in 2017 and it remained the leading cause of mortality in 
England and Wales, accounting for 12.7% of all deaths registered 
(Office for National Statistics, 2018). The Lancet Commission 
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on Dementia urges health professionals to be ambitious about 
prevention, arguing that pushing back the age of dementia onset 
would bring enormous benefits, since it has been suggested that 
a delay in onset of 1 year could prevent more than 9 million cases 
of dementia by 2050, and a delay in onset of 5 years could halve 
the prevalence of dementia globally (Livingston et al, 2017).
While there is greater understanding of the pathophysiology 
of Alzheimer’s disease, its causation has yet to be fully uncovered 
and it is likely to be multifactorial; age and genetics are certainly 
implicated. Medical conditions, such as stroke, diabetes and 
hypertension, may also contribute to an increased risk of 
Alzheimer’s disease and its subsequent disease course (Edwards 
et al, 2019). More recently, there has been increasing evidence 
of other potentially modifiable risk factors (MRFs), including 
nutrition (Antal et al, 2017), physical exercise (Brini et al, 2018), 
social engagement (Hersi et al, 2017), cognitive stimulation 
(Yates et al, 2016), smoking (Durazzo et al, 2014) and alcohol 
consumption (Ballard and Lang, 2018), which appear to play 
a significant role. Alongside this, the evidence base relating to 
the prevention of dementia has been accumulating steadily. 
In 2014, the World Dementia Council asked the Alzheimer’s 
Association to evaluate and report on the state of the evidence 
on MRFs for cognitive decline and dementia, and a summary 
of this evaluation was subsequently published by Baumgart et al 
(2015), in which the authors assert that the issue of addressing 
MRFs for dementia can no longer solely be a matter of 
academic discussion, but requires action. Consistent with this, 
the Department of Health and Social Care (DHSC) (2018) has 
recently outlined its vision for prevention, which affirms that 
we can make healthy lifestyle choices to reduce our chances 
of getting conditions such as dementia. 
In keeping with these calls for action, a multidisciplinary 
advisory group of health professionals involved in dementia 
care was convened in January 2018 in the UK to review the 
current evidence base regarding MRFs for early Alzheimer’s 
disease and mild cognitive impairment (MCI), and to generate a 
user-friendly aide memoire to assist positive interventions in the 
clinical arena. The advisory group comprised seven individuals 
from a variety of disciplines, including a consultant geriatrician, 
dietitian, clinical specialist physiotherapist, consultant nurse for 
dementia, clinical nurse specialist in older persons’ mental health, 
lecturer in psychology, and specialist in dementia education. 
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During the meeting, the advisors discussed evidence from 
published literature and their clinical experience of working 
in dementia, and reached agreement on the issues and 
recommendations they considered were most important. This 
article is an outcome of that meeting, its objectives being to 
raise awareness of the issues that are most applicable to nurses, 
and to provide practical guidance on how nurses may actively 
seek to address MRFs for early Alzheimer’s disease and MCI 
in clinical practice.
Modifiable risk factors for early Alzheimer’s 
disease and mild cognitive impairment
Based on their assessment of the published literature and 
personal experience, the advisors determined that MRFs for 
early Alzheimer’s disease and MCI fall broadly into four areas 
where there is evidence to support interventions that may help 
delay cognitive decline or reduce the risk of developing the 
disease. These areas are categorised as medical, psychosocial, 
lifestyle and nutrition (Table 1). What follows is a summary of 
the key evidence identified and discussed by the panel relating 
to each of these categories. 
Medical
There is evidence for a link between a number of cardiovascular 
risk factors and dementia. Such risk factors include diabetes, 
mid-life hypertension, obesity and mid-life hyperlipidaemia. 
Other factors categorised within the medical domain include 
anticholinergic medications and hearing loss.
Evidence has shown a greater likelihood of individuals with 
diabetes having lower cognitive performance and an increased 
risk of dementia, concluding that the association between 
diabetes and dementia appears strong, although it is inconclusive 
(Baumgart et al, 2015). Furthermore, Baumgart et al ( 2015) cite 
a meta-analysis that demonstrated that individuals with MCI 
and diabetes were more likely to progress to dementia than 
those with MCI and no diabetes (Cooper et al, 2015). Some 
evidence suggests that diabetes increases dementia risk not only 
through vascular pathways but also through the interactions of 
other biological mechanisms related to diabetes itself, such as 
insulin resistance, impaired glucose metabolism, the presence 
of advanced glycation end products and β-amyloid formation 
(Mushtaq et al, 2014).
A systematic review of meta-analyses, observational studies 
and randomised controlled trials found that treatments for 
hypertension (in particular, calcium channel blockers and renin-
angiotensin system blockers) may reduce the risk of cognitive 
decline and dementia (Rouch et al, 2015).
Evidence from several meta-analyses, systematic reviews 
and individual prospective studies has demonstrated that mid-
life obesity is associated with an increased risk of dementia 
(Baumgart et al, 2015). Furthermore, Dye et al (2017) reported 
that, in addition to an increased risk of an accelerated cognitive 
decline with ageing, there is evidence to suggest that obesity in 
early-to-mid adulthood may have an immediate detrimental 
impact on cognitive functioning (Dye et al, 2017).
Research into a potential link between hyperlipidaemia 
(elevated cholesterol) in mid and late life and the risk of 
dementia has yielded inconsistent findings, and no association 
between hyperlipidaemia and vascular dementia has been 
found (Baumgart et al, 2015). A meta-analysis of evidence 
for an association between serum cholesterol and the risk of 
late-life dementia, derived from over 23 000 subjects from 17 
studies, led to the conclusion that high mid-life total cholesterol 
increases the risk of late-life Alzheimer’s disease, but the study 
also acknowledged that significant gaps in the evidence remain 
(Anstey et al, 2017). Observational studies of patients taking 
statins have seemed to show a reduction in the risk of dementia, 
although more robust cohort studies have thus far failed to 
reproduce these findings (Baumgart et al, 2015). Moreover, 
a Cochrane review of randomised, double-blind, placebo-
controlled trials, in which people at risk of dementia were 
treated with statins for at least 12 months, concluded that 
statins given in later life to people at risk of vascular disease 
do not prevent cognitive decline or dementia (McGuinness 
et al, 2016). 
It is widely acknowledged that anticholinergic medications 
have a detrimental impact on cognitive performance (Richardson 
et al, 2018; López-Álvarez et al, 2019). Due to increasing 
health complications in later life, the use of polypharmacy 
in elderly people is high, and many commonly prescribed 
drugs have anticholinergic effects, including neuropsychiatric 
drugs (eg tricyclic antidepressants, antipsychotic agents, anti-
epileptic drugs, antiparkinsonian medication) and a range of 
non-psychoactive drugs (eg antihistamines, antispasmodics, anti-
ulcer agents, bronchodilators, diuretics, corticoids, cardiovascular 
medications) (López-Álvarez et al, 2019). A UK case-control 
study conducted in over 40 000 patients with dementia aged 
65–99 years and approximately 284 000 control subjects without 
dementia found that dementia was associated with an increasing 
average anticholinergic cognitive burden (ACB) score, and a 
strong association between some classes of anticholinergic drugs 
(eg antidepressants, urological agents, and antiparkinsonian 
drugs) and future dementia incidence (Richardson et al, 2018). 
Table 1. Modifiable risk factors for early Alzheimer’s 
disease and mild cognitive impairment, by domain
Domain Risk factors
Medical  ■ Vascular risk factors: diabetes, hypertension, 
obesity, hyperlipidaemia  
 ■ Anticholinergic medications 
 ■ Hearing loss
Psychosocial  ■ Depression 
 ■ Anxiety
 ■ Lack of social interaction
 ■ Lack of cognitive leisure activities 
 ■ Loneliness
 ■ Isolation
Lifestyle  ■ Lack of physical activity 
 ■ Smoking 
 ■ Alcohol consumption
Nutrition  ■ Poor diet 
 ■ Lack of nutritional precursors and co-factors 
for phospholipid membrane formation
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Similarly, a large nested case-control study, conducted in more 
than 280 000 patients with a diagnosis of dementia and matched 
controls, clearly demonstrated that exposure to several types 
of strong anticholinergic drugs (including antidepressants, 
antiparkinsonian agents, antipsychotic medications, and anti-
epileptic drugs) is associated with an increased risk of dementia, 
the association being particularly strong in those diagnosed 
before the age of 80 years (Coupland et al, 2019). 
Age-related hearing loss is associated with the risk of 
developing dementia (Uchida et al, 2019). In a cross-sectional 
analysis of the English Longitudinal Study of Ageing (ELSA), 
participants who had self-reported or objectively assessed 
moderate and poor hearing were more likely to have a dementia 
diagnosis than those with normal hearing, after adjusting for 
potential confounders (Davies et al, 2017). Longitudinally, 
when compared with those with normal hearing, the hazard 
of developing dementia was about 40% higher in individuals 
who self-reported moderate hearing (hazard ratio, 1.39; 95% 
confidence interval, 1.01–1.92) and about 60% higher in 
those who self-reported poor hearing (hazard ratio, 1.57; 95% 
confidence interval, 1.12–2.02) (Davies, 2017). In a further 
cross-sectional analysis of ELSA, the association between 
objectively measured hearing loss and poor cognition was seen 
only in individuals with untreated hearing loss (ie those who did 
not use hearing aids), and social isolation appeared to mediate 
the association, leading the authors to conclude that cognitive 
decline associated with age-related hearing impairment is likely 
to be preventable by increased screening in the elderly and 
early rehabilitation (Ray et al, 2018). In a meta-analysis of 
36 studies involving more than 20 000 participants, a small 
but significant association was found for age-related hearing 
loss within all domains of cognitive function, and significant 
associations were found between age-related hearing loss and 
both cognitive impairment and dementia (Loughrey et al, 2018). 
Age-related hearing loss therefore represents an MRF and 
possible biomarker for cognitive decline, cognitive impairment, 
and dementia (Loughrey et al, 2018). 
Psychosocial
Several psychosocial factors have been identified as being 
associated with dementia, and these may therefore represent 
potential MRFs for early Alzheimer’s disease and MCI. These 
not only include psychiatric conditions, such as depression, 
but also social factors, including social engagement, cognitive 
stimulation and loneliness.
The risk of dementia has been found to be higher among 
individuals with depression and there appears to be a link between 
cognitive decline and symptoms of depression (Mirza et al, 2016). 
However, it is not entirely clear whether depression is a risk factor 
for dementia, or an early indication of changes associated with 
the condition. Barnes et al (2012) conducted a large retrospective 
cohort study of more than 13 500 members of a medical care 
programme who underwent a voluntary multiphasic health 
check-up, and found that there was an increased risk for dementia 
among those with mid-life and late-life depression (Barnes et 
al, 2012). When they examined the incidence of Alzheimer’s 
disease and vascular dementia separately, subjects who only had 
late-life depressive symptoms had a twofold increase in the risk 
of Alzheimer’s disease, whereas those with both mid-life and 
late-life symptoms had more than a threefold increase in the 
risk of vascular dementia (Barnes et al, 2012).
Public Health England (PHE) (2016) reported that data 
from 22 studies that included more than 29 000 participants 
demonstrate a 46% lower risk of dementia among people 
with high levels of mental activity in comparison with 
those with low mental activity. The authors of the report 
argue that being socially active can help reduce the risk of 
dementia by improving mood, relieving stress, reducing the 
risk of depression and reducing loneliness (PHE, 2016). The 
Alzheimer’s Society (2019b) refers to the maxim ‘use it or lose 
it’ when recommending that a daily ‘brain workout’, using 
puzzles, word searches or crosswords, might help reduce the 
risk of dementia. Similarly, learning a new language may equip 
the brain with resources that make it more resilient to brain 
diseases such as the dementias (Alzheimer’s Society, 2019b). A 
Cochrane review identified many randomised controlled trials 
of mental engagement/cognitive training interventions that have 
demonstrated improvements in immediate and delayed recall 
among those in the treatment group compared with controls 
(Martin et al, 2011). 
In an analysis of data from the Health and Retirement Study, 
which included over 12 000 participants who were followed up 
for 10 years, loneliness was found to be associated with a 40% 
increased risk of dementia (Sutin et al, 2018). This association 
was found to be independent of social isolation (living alone, 
unmarried, without social support), reflecting similar findings 
from other studies, which have reported that feelings of 
loneliness, rather than social isolation, predict dementia onset 
(Holwerda et al, 2014).
Lifestyle 
In addition to psychosocial factors, several lifestyle factors have 
been identified as important MRFs for dementia.
Physical activity has a range of health benefits, including 
contributing to a reduced risk of cerebrovascular and 
cardiovascular diseases, such as diabetes, obesity and hypertension. 
In a review of the evidence for the benefits of regular exercise, 
Ahlskog et al (2011) concluded that ongoing, moderate-intensity 
physical exercise should be recommended for all ages as a means 
of lowering cognitive risk and slowing cognitive decline. A more 
recent systematic review and meta-analysis of longitudinal 
studies on the relationship between physical activity and the 
risk of cognitive decline, all-cause dementia, Alzheimer’s disease 
and vascular dementia confirmed the importance of physical 
activity as an MRF—it found that high physical activity is 
more protective against Alzheimer’s disease (odds ratio [95% 
confidence interval], 0.62 [0.49, 0.75]) than it is against cognitive 
decline (0.67 [0.55, 0.78]) and all-cause dementia (0.79 [0.69, 
0.88]), and non-protective against vascular dementia (0.92 [0.62, 
1.30]) (Guure et al, 2017). 
Cardiovascular disease, stroke, diabetes, hypertension and 
hypercholesterolaemia have been individually cited as MRFs 
for Alzheimer’s disease and vascular dementia (Gottesman et 
al, 2017; Ngandu et al, 2015) and, because smoking is linked 
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with increased risk for the development of these conditions, it 
follows that smoking is also an MRF, regardless of any evidence 
of a direct link to dementia. Consistent with this, a systematic 
review of published studies (Durazzo et al, 2014) concluded 
that the cumulative body of research indicates that previous 
and active smoking is associated with a significantly increased 
risk for Alzheimer’s disease.
The effect of alcohol consumption on the risk of dementia is 
less clear. Studies suggest a U-shaped relationship between regular 
alcohol consumption and cognitive function: frequent heavy 
consumption decreases cognitive performance, whereas regular 
light and moderate consumption may have a protective impact 
(Gutwinski et al, 2018). Chronic heavy alcohol consumption can 
cause thiamine (vitamin B1) deficiency and lead to Korsakoff ’s 
syndrome, characterised by symptoms including confabulation, 
disorientation, severe memory loss and amnesia (Arts et al, 2017; 
Rehm et al, 2019; Wiegmann et al, 2020).
Nutrition 
Maintaining a healthy diet is beneficial for any patient. The 
NHS (2018) advocates eating at least five portions of a variety 
of fruit and vegetables every day, based on advice from the 
World Health Organization (2005), which recommends eating 
a minimum of 400 g of fruit and vegetables a day to lower the 
risk of chronic conditions, such as heart disease, cancer, diabetes, 
and obesity. Emerging evidence suggests that maintaining a 
healthy diet can protect against cognitive decline, possibly due to 
associated reductions in cardiovascular risk factors (Scarmeas et 
al, 2006; Morris et al, 2015; Vandewoude et al, 2016; Berendsen 
et al, 2017; Cherbuin and Walsh, 2019). Such diets include the 
Mediterranean diet, which can be broadly described as one 
containing relatively little red meat, with a focus on including 
whole grains, fruits and vegetables, fish, nuts and olive oil. A 
systematic review (Petersson and Philippou, 2016) indicated 
that subjects who had a high Mediterranean diet score (ie 
those who consumed a diet almost entirely of this nature) had 
a reduced risk of cognitive decline. 
Because hypertension is a potential MRF for dementia, diets 
that specifically target hypertension may also have relevance in 
reducing the risk of dementia. The Dietary Approaches to Stop 
Hypertension (DASH) eating plan (Sacks et al, 1999) requires no 
special foods, but provides daily and weekly nutritional goals, and 
recommends eating vegetables, fruits, whole grains, fat-free or 
low-fat dairy products, fish, poultry, beans, nuts and vegetable oils 
(Association of UK Dietitians, 2017; Mayo Clinic 2019). Foods 
that are high in saturated fat, and sugar-sweetened beverages 
and sweets, are limited. A systematic review and meta-analysis 
demonstrated that the DASH diet can have a beneficial impact 
on blood pressure in adults, significantly reducing systolic blood 
pressure by 6.74 mmHg (95% confidence interval, -8.25, -5.23) 
and diastolic blood pressure by 3.54 mmHg (95% confidence 
interval, -4.29, -2.79) (Saneei et al, 2014). Since diabetes, 
pre-diabetes and high ‘normal’ blood glucose levels have also 
been linked to neurodegenerative processes, diets that limit 
carbohydrate intake have also been proposed as a potential 
preventive tool (Wlodarek et al, 2019).
Effective dietary interventions can have far-reaching 
implications for public health, especially with the growing 
burden of dementia in an ageing population. High-quality 
diets, such as the Mediterranean and DASH diets, can be further 
modified and simplified, such as in the Mediterranean-DASH 
Intervention for Neurodegenerative Delay (MIND) diet, 
to provide better protection against dementia (Morris et al, 
2015). The MIND diet, for instance, emphasises the dietary 
components and servings linked to neuroprotection and 
dementia prevention, but promotes lower servings than those 
specified for the DASH or Mediterranean diet (Morris et al, 
2015), which can potentially improve adherence. 
Synaptic loss is an important feature of early Alzheimer’s 
disease and the formation of new synapses is dependent on 
key nutritional elements that are known to be deficient in 
people with the disease, such as omega-3 fatty acids (Jicha and 
Markesbery, 2010), folate and vitamins B12, C and E (Glasø 
et al, 2004; Smach et al, 2011), as well as other important 
micronutrients (Scheltens et al, 2012). There has therefore been 
a growing interest in recent years in nutritional supplementation 
as a way to maintain a ‘healthy brain’ and reduce cognitive 
decline (Vandewoude et al, 2016). Previous studies have looked 
at a range of nutritional factors to modify clinical progression 
of Alzheimer’s disease (Le Bars et al, 1997; Freund-Levi et al, 
2006; Smith et al, 2010; Jernerén et al, 2015; Charemboon and 
Jaisin, 2015). 
While the correction of specific deficiencies is necessary 
to improve nutritional status, currently there is no generally 
applicable evidence to recommend the use of single-agent 
micronutrient supplementation at any stage of dementia or 
for prevention (Vandewoude et al, 2016; Rutjes et al, 2018). 
Conversely, there is emerging evidence that supplementation with 
a combination of such micronutrients may be more promising, 
consistent with the fact that a deficiency in any precursor has 
the potential to be a rate limiting step in the Kennedy cycle, the 
biochemical pathway involved in the synthesis of phospholipids 
required for the formation of neuronal membranes and synapses 
(Sakamoto et al, 2007; Rasmussen, 2019). 
An example of such a multi-nutrient combination, 
which has been tested in the clinical trial setting, is Fortasyn 
Connect—a  combination of docosahexaenoic acid; 
eicosapentaenoic acid; uridine monophosphate; choline; 
vitamins B12, B6, C, E, and folic acid; phospholipids; and 
selenium (van Wijk et al, 2014). Souvenaid, which contains 
the nutritional combination Fortasyn Connect, is described by 
the manufacturer as ‘a food for special medical purposes for the 
dietary management of early Alzheimer’s disease’. Two previous 
randomised clinical trials in patients with mild Alzheimer’s 
disease dementia reported that daily intake of Fortasyn Connect 
for 3 or 6 months improved memory performance (Scheltens 
et al, 2010; 2012). LipiDiDiet, which was the first randomised, 
controlled, double-blind trial in prodromal Alzheimer’s disease, 
showed that Fortasyn Connect had no significant effect on 
the primary endpoint of cognitive performance using a 
neuropsychological test battery over 2 years (Soininen et 
al, 2017). However, it demonstrated significant benefit on 
secondary endpoints, including domains of cognition affected 
by Alzheimer’s disease and hippocampal atrophy. It is anticipated 
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that an intervention such as this would take time to have an 
effect and would benefit people earlier in their disease course. 
Multi-nutrient supplementation during early Alzheimer’s 
disease, either alone or in combination with other prevention 
strategies, may therefore warrant further investigation. 
Interventions aimed at targeting modifiable 
risk factors
There is clearly a strong and developing evidence base relating 
to the role of MRFs in the aetiology of early Alzheimer’s disease 
and MCI. What is also clear is that this is a multifactorial issue, 
there being no single key factor to target for reducing the risk 
of cognitive decline, dementia and the disease. Consequently, 
the advisory group sought to make recommendations that 
support a multi-domain approach to intervention. In so doing, 
it agreed on a range of pragmatic interventional approaches 
that fall within the remit of health professionals in general, and 
nurses in particular. These interventions are presented below 
as they relate to the four domains identified earlier (see also 
Figure 1). Additional resources relating to these domains are 
provided in Box 1. 
Interventions related to medical factors 
 ■ Ensure blood pressure is optimal: 
 – Has the person had their blood pressure checked recently? 
 – Is there awareness that optimal blood pressure is less than 
140/90 mmHg? 
 – Does the person need signposting to their GP for current 
blood pressure reading?
 ■ Ensure body mass index (BMI) is optimal: 
 – A BMI of 18.5–24.9 kg/m2 (18.5–22.9 kg/m2 for adults 
from South Asia) is considered to be in the healthy weight 
range. A BMI of less than 18.5 kg/m2 is considered low 
and the person may require dietary advice
 ■ Ensure cholesterol level is optimal: 
 – Has the person had their cholesterol checked recently? 
This should be ≤5 mmol/L for healthy adults
 ■ Ensure there is no undiagnosed diabetes or, if the person 
has diabetes, ensure control is optimal for age
 ■ Review medicines and assess for anticholinergic cognitive 
burden (ACB): 
 – When did the person last have a review of their current 
medication? 
 – Does the person know they can make an appointment 
with their GP or pharmacist to discuss their medication? 
 – Calculating the potential ACB in patients can be easily 
facilitated by using a recognised scale, such as the ACB 
Calculator (www.ACBcalc.com)
 ■ Ensure any hearing loss is addressed. Regular hearing checks 
are recommended
Interventions related to psychosocial factors 
 ■ Adequately treat depression and anxiety: 
 – Many of the things that can cause people to feel depressed 
can also cause them to feel anxious, and vice versa
 – Identification and treatment of depression is best enabled 
by the person’s GP and/or mental health professionals. 
However, the starting point is often a recognition by the 
person: the simple act of asking someone how their mood 
is can be an important trigger
 ■ Signpost opportunities for increasing social engagement: 
 – Being socially active can help reduce the risk of dementia 
by improving mood, relieving stress, reducing the risk of 
depression and reducing loneliness
 – Encourage the person to try to keep in touch with the 
people who are important to them, such as friends and 
family. Volunteering, or joining a club or community 
group, are also good ways to stay socially active
 – Health professionals can have a significant role for 
signposting opportunities to increase social engagement, 
but this is reliant on some form of assessment of the 
person’s level of social activity
 ■ Advise on methods of cognitive training:
 – There is increasing evidence that daily ‘brain workouts’ 
such as doing puzzles, word searches or crosswords, playing 
cards or learning something new, such as another language, 
can help reduce the risk of dementia (Yates et al, 2016; 
Fissler et al, 2018)
Interventions related to lifestyle factors
 ■ Encourage physical activity and exercise:
 – Physical activity has a range of health benefits, including 
contributing to a reduced risk of heart attacks and stroke, 
diabetes, obesity and dementia. It also has a positive impact 
on mood and mental wellbeing
 – Encourage the person to try to take regular physical 
activity: this may be a brisk walk, cleaning or gardening. 
It may be as little as 10 minutes a day, building up over 
time. Ideally, individuals should aim to achieve 150 minutes 
of physical activity a week, which can be spread out over 
the day and throughout the week into bite-size pieces 
 – Local leisure centres may well be offering initiatives such 
as free exercise classes or a free swim on certain days of 
the week to encourage people to get in shape. The NHS 
website Get Fit for Free is a useful starting point (www.
nhs.uk/live-well/exercise/free-fitness-ideas) 
 ■ Advise and signpost smoking reduction and cessation support: 
 – Smoking has been linked to an increased risk of heart 
and lung conditions, diabetes and cancers. These are all 
known risk factors for developing Alzheimer’s disease and 
vascular dementia
 – Health professionals can play a pivotal role in assisting 
individuals to consider giving up smoking. Importantly, 
they can signpost comprehensive support resources such 
as NHS Smoke free (www.nhs.uk/smokefree/)
 ■ Advise alcohol intake in line with current accepted unit 
guidelines: 
 – Current guidelines state that men and women should not 
drink more than 14 units of alcohol each week
 – One unit of alcohol is measured as 10 mL or 8 g of pure 
alcohol, equating, approximately, to one 25 mL single 
measure of whisky (alcohol by volume (ABV) 40%), a 
third of a pint of beer (ABV 5–6%) or half a standard 
(175 mL) glass of red wine (ABV 12%).
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Interventions related to nutritional factors
 ■ Advise on dietary principles around maintaining general health: 
 – Current thinking points to aiming for five portions of 
fruit and vegetables a day (https://www.nhs.uk/live-well/
eat-well/why-5-a-day) (NHS website, 2018). Protein, such 
as oily fish, beans, pulses, eggs or lean meat, should be 
consumed at least twice a day 
 – Limit sugar intake and be aware of hidden salt. Starchy 
foods, such as bread, potatoes and pasta, are recommended, 
as are wholegrain varieties, wherever possible
 – Saturated fat intake should be limited
 – 1.2 L (approximately six to eight glasses) of fluid (such 
as water, lower-fat milk and sugar-free drinks) a day is 
considered optimal
 – This advice aligns closely with the Mediterranean-style 
diet, which is characterised by eating plenty of fruit, 
vegetables, legumes and cereals; it includes oily fish in 
the diet; eating less meat; choosing products that are low 
in sugar and saturated fat; choosing products made from 
vegetable and plant oils, such as olive oil; and having 
moderate alcohol intake
 ■ Signpost evidence-based nutritional supplements: 
 – As with medication, many people can find themselves 
taking a cocktail of nutritional supplements. A review with 
some rationalisation of such intake might be of benefit 
,given the ambiguity of the evidence base
 – In people who have received a diagnosis of Alzheimer’s 
disease or MCI, Souvenaid may be helpful. Souvenaid 
* 18.5–22.9 kg/m2 for adults from South Asia.  
BMI=body mass index; DASH=Dietary Approaches to Stop Hypertension
Diagnosis of mild cognitive impairment/signs of early Alzheimer’s disease
Figure 1. Pragmatic approaches for nurses to help address modifiable risk factors for early Alzheimer’s disease and mild cognitive impairment in 
their patients






 ■ Vascular risk 
 ■ Anticholinergic medicines 
Factors
 ■ Depression/apathy/anxiety
 ■ Feelings of loneliness 
 ■ Lack of social interaction 
 ■ Isolation 
 ■ Lack of cognitive leisure activities
Factors:
 ■ Lack of physical activity 
 ■ Smoking 
 ■ Alcohol consumption
Factors
 ■ Lack of nutritional precursors 
and co-factors for phospholipid 
membrane formation
 ■ Poor diet
Medical
Patient review
 ■ How is your vascular health? 
 ■ How is your blood pressure?
 ■ How is your weight? 
 ■ How is your cholesterol? 
 ■ What medicines do you currently 
take?
Notes
 ■ Ensure blood pressure is optimal: 
<140/90 mmHg
 ■ Ensure BMI is optimal: 
18.5-24.9 kg/m2*
 ■ Ensure cholesterol level is optimal: 
<5 mmol/L
 ■ Ensure no undiagnosed diabetes, 
or if diabetic ensure optimal 
control 
 ■ Review medicines and assess for 
anticholinergic burden 
 ■ Ensure hearing loss is addressed 
Notes
 ■ Adequately treat depression and 
anxiety 
 ■ Advise on methods of cognitive 
training, eg doing crosswords, 
playing cards, learning another 
language  
 ■ Signpost opportunities for 
increasing social engagement, 
eg spending more time with friends 
and family, volunteering, joining a 
club or social group
Notes
 ■ Advise and signpost smoking 
reduction and cessation support, 
eg NHS Smoke Free
 ■ Advise alcohol intake in line with 
currently accepted unit guidelines: 
14 units/week for men and women
 ■ Encourage physical activity and 
exercise, ideally aiming to achieve 
150 min of physical activity a week, 
eg taking a brisk walk, cleaning, 
gardening, taking an exercise class 
Notes
 ■ Assess patient’s general 
appearance 
 ■ Signpost evidence-based medical 
nutritional interventions 
 ■ Advise on dietary principles around 
maintaining general health, eg 
five portions of fruit/vegetables 
per day, eating wholegrain bread/
pasta etc
 ■ Signpost diets with evidence of 




 ■ How is your mental health? 
 ■ What is your level of social 
activity? 
 ■ Do you feel you are lonely? 
 ■ Have you suffered/are you 
suffering with your mood and 
anxiety? 
 ■ How often do you read or do 
puzzles such as crosswords?
Lifestyle
Patient review
 ■ How is your lifestyle? 
 ■ Are you a smoker? 
 ■ How many units of alcohol do you 
drink in a week? 
 ■ How physically active are you?
Nutrition
 Patient review
 ■ What medical nutritional 
interventions do you take? 
 ■ How is your diet? 
 ■ What do you typically eat in a day? 
 ■ Do you eat fish at least twice/week 
 ■ Do you eat pulses regularly? 
 ■ How much fruit and vegetables do 
you eat in a day? 
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is ‘a food for special medical purposes for the dietary 
management of early Alzheimer’s disease’ and must be 
used under the supervision of a health professional. It 
contains Fortasyn Connect and needs to be purchased 
by the individual.
Conclusion
Nurses occupy a position of trust in society and are ideally 
placed to offer information and advice to those for whom 
they care. The potential for population-based health gains is 
nowhere more potent than in regard to the prevention of 
dementia. Nurses are ideally placed to offer advice in this area 
and this article has aimed to provide the rationale for such 
action. Additionally, it seeks to raise awareness among nurses 
so that barriers to addressing this increasingly important area 
of health promotion are lowered. We hope that nurses, assisted 
by reference to the evidence-based interventions spanning four 
major domains, will gain confidence to increasingly use their 
discussion/conversations with patients around lifestyle choices 
and changes so that MRFs for early Alzheimer’s disease and 
MCI are addressed directly. In so doing, nurses will play an 
important role in helping to address this growing healthcare 
challenge. BJN
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CPD reflective questions
 ■ How do you think the phrase ‘prevention is better than cure’ relates to dementia care today?
 ■ In terms of the current evidence base, what types of modifiable risk factors (MRFs) are associated with early Alzheimer’s disease and 
mild cognitive impairment (MCI)?
 ■ Which of these MRFs do you think are most relevant to the patients whom you see in your everyday practice?
 ■ As a nurse, what steps can you take/what advice can you give to help address MRFs for early Alzheimer’s disease and MCI in 
your patients?
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